Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation
Abstract
:1. Introduction
2. Results and Discussion
2.1. ATO Induces ROS and p-AKT in LSC-Enriched AML Progenitor Cells
2.2. ATO-Induced ROS Activation Is Attenuated by Concomitant Activation of the p-Akt/Nrf2 Antioxidant Pathway in LSC-Enriched AML Progenitor Cells
2.3. Addition of VEN to ATO Inhibits Nrf2 Nuclear Translocation, Augments ROS and Increases Apoptosis in LSC-Enriched AML Progenitor Cells
2.4. Addition of VEN to ATO Inhibits Mitochondrial Metabolism in LSC-Enriched AML Progenitor Cells
2.5. Addition of VEN to ATO Inhibits Mitochondrial Metabolism in VEN-Resistant and -Sensitive LSC-Enriched AML Progenitor Cells
3. Materials and Methods
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Felipe Rico, J.; Hassane, D.C.; Guzman, M.L. Acute myelogenous leukemia stem cells: From Bench to Bedside. Cancer Lett. 2013, 338, 4–9. [Google Scholar] [CrossRef] [PubMed]
- Lagadinou, E.D.; Sach, A.; Callahan, K.; Rossi, R.M.; Neering, S.J.; Minhajuddin, M.; Ashton, J.M.; Pei, S.; Grose, V.; O’Dwyer, K.M.; et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12, 329–341. [Google Scholar] [CrossRef] [PubMed]
- Mattes, K.; Vellenga, E.; Schepers, H. Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: A potential window for leukemia therapy. Crit. Rev. Oncol. Hematol. 2019, 144, 102814. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.L.; Stevens, B.M.; D’Alessandro, A.; Reisz, J.A.; Culp-Hill, R.; Nemkov, T.; Pei, S.; Khan, N.; Adane, B.; Ye, H.; et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell 2018, 34, 724–740.e4. [Google Scholar] [CrossRef]
- Chapuis, N.; Poulain, L.; Birsen, R.; Tamburini, J.; Bouscary, D. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front. Oncol. 2019, 9, 405. [Google Scholar] [CrossRef] [PubMed]
- Jordan, C.T. Can we selectively target AML stem cells? Best Pract. Res. Clin. Haematol. 2019, 32, 101100. [Google Scholar] [CrossRef]
- Gross, A. BCL-2 family proteins as regulators of mitochondria metabolism. Biochim. Biophys. Acta 2016, 1857, 1243–1246. [Google Scholar] [CrossRef]
- Pollyea, D.A.; Stevens, B.M.; Jones, C.L.; Winters, A.; Pei, S.; Minhajuddin, M.; D’Alessandro, A.; Culp-Hill, R.; Riemondy, K.A.; Gillen, A.E.; et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018, 24, 1859–1866. [Google Scholar] [CrossRef]
- DiNardo, C.D.; Jonas, B.A.; Pullarkat, V.; Thirman, M.J.; Garcia, J.S.; Wei, A.H.; Konopleva, M.; Dohner, H.; Letai, A.; Fenaux, P.; et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl. J. Med. 2020, 383, 617–629. [Google Scholar] [CrossRef]
- Konopleva, M.Y. Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax. Best Pract. Res. Clin. Haematol. 2021, 34, 101251. [Google Scholar] [CrossRef]
- Stevens, B.M.; Jones, C.L.; Pollyea, D.A.; Culp-Hill, R.; D’Alessandro, A.; Winters, A.; Krug, A.; Abbott, D.; Goosman, M.; Pei, S.; et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Cancer 2020, 1, 1176–1187. [Google Scholar] [CrossRef] [PubMed]
- Buettner, R.; Nguyen, L.X.T.; Morales, C.; Chen, M.H.; Wu, X.; Chen, L.S.; Hoang, D.H.; Hernandez Vargas, S.; Pullarkat, V.; Gandhi, V.; et al. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J. Hematol. Oncol. 2021, 14, 70. [Google Scholar] [CrossRef] [PubMed]
- Bonati, A.; Rizzoli, V.; Lunghi, P. Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug. Curr. Pharm. Biotechnol. 2006, 7, 397–405. [Google Scholar] [CrossRef] [PubMed]
- Hoonjan, M.; Jadhav, V.; Bhatt, P. Arsenic trioxide: Insights into its evolution to an anticancer agent. J. Biol. Inorg. Chem. 2018, 23, 313–329. [Google Scholar] [CrossRef]
- Cho, H.; Jang, J.E.; Eom, J.I.; Jeung, H.K.; Chung, H.; Kim, J.S.; Cheong, J.W.; Min, Y.H. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells. Exp. Hematol. Oncol. 2021, 10, 28. [Google Scholar] [CrossRef]
- Shen, Z.X.; Shi, Z.Z.; Fang, J.; Gu, B.W.; Li, J.M.; Zhu, Y.M.; Shi, J.Y.; Zheng, P.Z.; Yan, H.; Liu, Y.F.; et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 2004, 101, 5328–5335. [Google Scholar] [CrossRef]
- Parmar, S.; Rundhaugen, L.M.; Boehlke, L.; Riley, M.; Nabhan, C.; Raji, A.; Frater, J.L.; Tallman, M.S. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk. Res. 2004, 28, 909–919. [Google Scholar] [CrossRef]
- Niu, C.; Yan, H.; Yu, T.; Sun, H.P.; Liu, J.X.; Li, X.S.; Wu, W.; Zhang, F.Q.; Chen, Y.; Zhou, L.; et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94, 3315–3324. [Google Scholar] [CrossRef]
- Chau, D.; Ng, K.; Chan, T.S.; Cheng, Y.Y.; Fong, B.; Tam, S.; Kwong, Y.L.; Tse, E. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J. Hematol. Oncol. 2015, 8, 46. [Google Scholar] [CrossRef]
- Leung, J.; Pang, A.; Yuen, W.H.; Kwong, Y.L.; Tse, E.W. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007, 109, 740–746. [Google Scholar] [CrossRef]
- Fu, W.; Zhu, G.; Xu, L.; Liu, J.; Han, X.; Wang, J.; Wang, X.; Hou, J.; Zhao, H.; Zhong, H. G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells. Cancer Cell Int. 2022, 22, 195. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, S.; Harigae, H.; Yokoyama, H.; Ishikawa, I.; Abe, S.; Imaizumi, M.; Sasaki, T.; Kaku, M. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication. Int. J. Hematol. 2006, 84, 256–261. [Google Scholar] [CrossRef] [PubMed]
- Lunghi, P.; Costanzo, A.; Salvatore, L.; Noguera, N.; Mazzera, L.; Tabilio, A.; Lo-Coco, F.; Levrero, M.; Bonati, A. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006, 107, 4549–4553. [Google Scholar] [CrossRef] [PubMed]
- Liang, C.; Peng, C.J.; Wang, L.N.; Li, Y.; Zheng, L.M.; Fan, Z.; Huang, D.P.; Tang, W.Y.; Zhang, X.L.; Huang, L.B.; et al. Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. Leuk. Lymphoma 2020, 61, 2692–2699. [Google Scholar] [CrossRef]
- Wang, R.; Li, Y.; Gong, P.; Gabrilove, J.; Waxman, S.; Jing, Y. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells. Mol. Cancer 2018, 17, 1871–1880. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Cai, J.; Zhu, J.; Lang, W.; Zhong, J.; Zhong, H.; Chen, F. Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress. Cancer Cell Int. 2020, 20, 250. [Google Scholar] [CrossRef]
- Chen, P.; Wu, J.; Yuan, Q.; Jiang, X.; Huang, H. The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002. Pharmazie 2015, 70, 322–327. [Google Scholar]
- Nagai, K.; Hou, L.; Li, L.; Nguyen, B.; Seale, T.; Shirley, C.; Ma, H.; Levis, M.; Ghiaur, G.; Duffield, A.; et al. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 2018, 9, 32885–32899. [Google Scholar] [CrossRef]
- Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931–947. [Google Scholar] [CrossRef]
- Perillo, B.; Di Donato, M.; Pezone, A.; Di Zazzo, E.; Giovannelli, P.; Galasso, G.; Castoria, G.; Migliaccio, A. ROS in cancer therapy: The bright side of the moon. Exp. Mol. Med. 2020, 52, 192–203. [Google Scholar] [CrossRef]
- Nguyen, L.X.T.; Troadec, E.; Kalvala, A.; Kumar, B.; Hoang, D.H.; Viola, D.; Zhang, B.; Nguyen, D.Q.; Aldoss, I.; Ghoda, L.; et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J. Cell Physiol. 2019, 234, 14040–14049. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.; Nioi, P.; Pickett, C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284, 13291–13295. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Li, L.; Yan, S.; Li, Z. Arsenic trioxide suppresses acute graft-versus-host disease by activating the Nrf2/HO-1 pathway in mice. Br. J. Haematol. 2019, 186, e145–e148. [Google Scholar] [CrossRef] [PubMed]
- De Nicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475, 106–109. [Google Scholar] [CrossRef]
- McCulloch, D.; Brown, C.; Iland, H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: Current perspectives. Onco Target 2017, 10, 1585–1601. [Google Scholar] [CrossRef]
- Valenzuela, M.; Glorieux, C.; Stockis, J.; Sid, B.; Sandoval, J.M.; Felipe, K.B.; Kviecinski, M.R.; Verrax, J.; Buc Calderon, P. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br. J. Cancer 2014, 111, 874–882. [Google Scholar] [CrossRef]
- Martelli, M.P.; Gionfriddo, I.; Mezzasoma, F.; Milano, F.; Pierangeli, S.; Mulas, F.; Pacini, R.; Tabarrini, A.; Pettirossi, V.; Rossi, R.; et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 2015, 125, 3455–3465. [Google Scholar] [CrossRef]
- El Hajj, H.; Dassouki, Z.; Berthier, C.; Raffoux, E.; Ades, L.; Legrand, O.; Hleihel, R.; Sahin, U.; Tawil, N.; Salameh, A.; et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood 2015, 125, 3447–3454. [Google Scholar] [CrossRef]
- Takahashi, S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med. Chem. 2010, 10, 504–510. [Google Scholar] [CrossRef]
- Karathedath, S.; Rajamani, B.M.; Musheer Aalam, S.M.; Abraham, A.; Varatharajan, S.; Krishnamurthy, P.; Mathews, V.; Velayudhan, S.R.; Balasubramanian, P. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE 2017, 12, e0177227. [Google Scholar] [CrossRef]
- Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J.D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13, 76–86. [Google Scholar] [CrossRef] [PubMed]
- Wakabayashi, N.; Itoh, K.; Wakabayashi, J.; Motohashi, H.; Noda, S.; Takahashi, S.; Imakado, S.; Kotsuji, T.; Otsuka, F.; Roop, D.R.; et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet 2003, 35, 238–245. [Google Scholar] [CrossRef] [PubMed]
- Venugopal, R.; Jaiswal, A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998, 17, 3145–3156. [Google Scholar] [CrossRef] [PubMed]
- Baird, L.; Dinkova-Kostova, A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85, 241–272. [Google Scholar] [CrossRef] [PubMed]
- Calvert, J.W.; Elston, M.; Nicholson, C.K.; Gundewar, S.; Jha, S.; Elrod, J.W.; Ramachandran, A.; Lefer, D.J. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 2010, 122, 11–19. [Google Scholar] [CrossRef]
- Wang, R.; Xia, L.; Gabrilove, J.; Waxman, S.; Jing, Y. Downregulation of Mcl-1 through GSK-3beta activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 2013, 27, 315–324. [Google Scholar] [CrossRef]
- Kang, K.W.; Lee, S.J.; Kim, S.G. Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal. 2005, 7, 1664–1673. [Google Scholar] [CrossRef]
- Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70, 440–446. [Google Scholar] [CrossRef]
- Panina, S.B.; Pei, J.; Kirienko, N.V. Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer Metab. 2021, 9, 17. [Google Scholar] [CrossRef]
- Dinkova-Kostova, A.T.; Abramov, A.Y. The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 2015, 88, 179–188. [Google Scholar] [CrossRef]
- Sporn, M.B.; Liby, K.T. NRF2 and cancer: The good, the bad and the importance of context. Nat. Rev. Cancer 2012, 12, 564–571. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hoang, D.H.; Buettner, R.; Valerio, M.; Ghoda, L.; Zhang, B.; Kuo, Y.-H.; Rosen, S.T.; Burnett, J.; Marcucci, G.; Pullarkat, V.; et al. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. Int. J. Mol. Sci. 2022, 23, 6568. https://doi.org/10.3390/ijms23126568
Hoang DH, Buettner R, Valerio M, Ghoda L, Zhang B, Kuo Y-H, Rosen ST, Burnett J, Marcucci G, Pullarkat V, et al. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. International Journal of Molecular Sciences. 2022; 23(12):6568. https://doi.org/10.3390/ijms23126568
Chicago/Turabian StyleHoang, Dinh Hoa, Ralf Buettner, Melissa Valerio, Lucy Ghoda, Bin Zhang, Ya-Huei Kuo, Steven T. Rosen, John Burnett, Guido Marcucci, Vinod Pullarkat, and et al. 2022. "Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation" International Journal of Molecular Sciences 23, no. 12: 6568. https://doi.org/10.3390/ijms23126568